Published in Metabolites on June 07, 2017
Special Issue: Cancer Metabolism. Metabolites (2017) 0.75
Awareness and current knowledge of breast cancer. Biol Res (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
On respiratory impairment in cancer cells. Science (1956) 14.07
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc (2007) 5.92
Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res (1999) 3.23
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Tumour phospholipid metabolism. NMR Biomed (1999) 2.74
Studies of human tumors by MRS: a review. NMR Biomed (1993) 2.44
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Cyclin D1 in breast cancer pathogenesis. J Clin Oncol (2005) 2.36
High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed (2002) 2.05
Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed (2006) 2.01
In vivo post-contrast 1H-MRS evaluation of malignant and benign breast lesions: a meta-analysis. Tumour Biol (2014) 1.99
Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results. Radiology (2001) 1.92
Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy. Magn Reson Med (2011) 1.87
Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging (1999) 1.82
Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer (2001) 1.73
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol (2010) 1.54
Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst (2002) 1.51
Human breast lesions: characterization with proton MR spectroscopy. Radiology (1998) 1.50
Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res (2010) 1.48
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer (2010) 1.46
Metabolite quantification and high-field MRS in breast cancer. NMR Biomed (2009) 1.45
Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res (2002) 1.40
Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA (2006) 1.40
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Phospholipid metabolites as indicators of cancer cell function. NMR Biomed (1993) 1.36
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed (1998) 1.27
MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat (2006) 1.25
The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat (2001) 1.23
Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T. Eur Radiol (2004) 1.21
Measurement and correction of respiration-induced B0 variations in breast 1H MRS at 4 Tesla. Magn Reson Med (2004) 1.21
Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T. Radiology (1988) 1.17
Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br J Cancer (2009) 1.16
Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR Biomed (2003) 1.12
Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer (2001) 1.11
Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson (1998) 1.10
An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS One (2011) 1.10
Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T--systematic review and meta-analysis. Radiology (2013) 1.09
31P MRSI and 1H MRS at 7 T: initial results in human breast cancer. NMR Biomed (2011) 1.07
1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed (1994) 1.07
Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones. Endocr Relat Cancer (2000) 1.06
MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed (2011) 1.03
Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. Semin Oncol (2004) 1.02
Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed (2010) 1.02
Quantitative correlation between (1)H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magn Reson Imaging (2007) 1.01
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res (2001) 1.00
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed (2012) 0.99
Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol (2006) 0.94
Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers. NMR Biomed (2012) 0.93
Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS. NMR Biomed (2010) 0.92
Analysis of cellular phosphoproteins by two-dimensional gel electrophoresis: applications for cell signaling in normal and cancer cells. Electrophoresis (1994) 0.91
Choline metabolism in breast cancer; 2H-, 13C- and 31P-NMR studies of cells and tumors. MAGMA (1998) 0.90
Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc (2006) 0.89
Proton MR spectroscopy in clinical routine. J Magn Reson Imaging (2001) 0.89
(31)P magnetic resonance spectroscopy of the breast and the influence of the menstrual cycle. Breast Cancer Res Treat (2014) 0.89
In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patients. NMR Biomed (2011) 0.89
Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapy. PLoS One (2013) 0.89
Imaging biochemistry: applications to breast cancer. Breast Cancer Res (2000) 0.88
MRS-based Metabolomics in Cancer Research. Magn Reson Insights (2014) 0.88
Hypoxic tumors and their effect on immune cells and cancer therapy. Methods Mol Biol (2010) 0.87
Human in-vivo 31P MR spectroscopy of benign and malignant breast tumors. Korean J Radiol (2001) 0.87
The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging. Eur Radiol (2011) 0.87
Intramolecular zero-quantum-coherence 2D NMR spectroscopy of lipids in the human breast at 7 T. Magn Reson Med (2014) 0.84
Diagnostic usefulness of water-to-fat ratio and choline concentration in malignant and benign breast lesions and normal breast parenchyma: an in vivo (1) H MRS study. J Magn Reson Imaging (2011) 0.82
Detection of alterations in membrane metabolism during neoadjuvant chemotherapy in patients with breast cancer using phosphorus magnetic resonance spectroscopy at 7 Tesla. Springerplus (2014) 0.82
Monitoring mammary tumor progression and effect of tamoxifen treatment in MMTV-PymT using MRI and magnetic resonance spectroscopy with hyperpolarized [1-(13) C]pyruvate. Magn Reson Med (2014) 0.82
Multiparametric MRI With Dynamic Contrast Enhancement, Diffusion-Weighted Imaging, and 31-Phosphorus Spectroscopy at 7 T for Characterization of Breast Cancer. Invest Radiol (2015) 0.81
Potential Clinical Roles for Metabolic Imaging with Hyperpolarized [1-(13)C]Pyruvate. Front Oncol (2016) 0.80
Differential diagnosis between malignant and benign breast lesions using single-voxel proton MRS: a meta-analysis. J Cancer Res Clin Oncol (2014) 0.80
Potential of Diffusion-Weighted Imaging in the Characterization of Malignant, Benign, and Healthy Breast Tissues and Molecular Subtypes of Breast Cancer. Front Oncol (2016) 0.80
Malignant breast tumor phospholipid profiles using (31)P magnetic resonance. Cancer Lett (2002) 0.79
Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: an MRI and in vivo proton MRS study. Magn Reson Med (2011) 0.79
Lipid composition changes in normal breast throughout the menstrual cycle. MAGMA (1997) 0.79
(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism. Front Oncol (2016) 0.78
Clinical Imaging of Tumor Metabolism with (1)H Magnetic Resonance Spectroscopy. Magn Reson Imaging Clin N Am (2016) 0.78
Study of normal breast tissue by in vivo volume localized proton MR spectroscopy: variation of water-fat ratio in relation to the heterogeneity of the breast and the menstrual cycle. Magn Reson Imaging (2009) 0.78
Evaluation of Cancer Metabolomics Using ex vivo High Resolution Magic Angle Spinning (HRMAS) Magnetic Resonance Spectroscopy (MRS). Metabolites (2016) 0.77
1H-MRS evaluation of breast lesions by using total choline signal-to-noise ratio as an indicator of malignancy: a meta-analysis. Med Oncol (2015) 0.76
1H/31P polarization transfer at 9.4 Tesla for improved specificity of detecting phosphomonoesters and phosphodiesters in breast tumor models. PLoS One (2014) 0.76
In vivo MR spectroscopy of human breast tissue: quantification of fatty acid composition at a clinical field strength (3 T). MAGMA (2016) 0.76
Proton observed phosphorus editing (POPE) for in vivo detection of phospholipid metabolites. NMR Biomed (2015) 0.76
Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA. Sci Rep (2017) 0.76
Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer. Front Oncol (2016) 0.75
Characterization of malignant breast tissue of breast cancer patients and the normal breast tissue of healthy lactating women volunteers using diffusion MRI and in vivo 1H MR spectroscopy. J Magn Reson Imaging (2013) 0.75
Proton and phosphorus magnetic resonance spectroscopy of the healthy human breast at 7 T. NMR Biomed (2016) 0.75
The Tumor Microenvironment Modulates Choline and Lipid Metabolism. Front Oncol (2016) 0.75
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging (2016) 0.75
Clinical Breast MR Using MRS or DWI: Who Is the Winner? Front Oncol (2016) 0.75